Media

PolyActiva completes recruitment in key Phase I glaucoma implant safety study. Six-month treatment period demonstrated.

24-07-2019

Media Announcements

July 23, Chicago – PolyActiva Pty Ltd, a clinical-stage biotechnology company and leader in ocular drug delivery, has completed patient enrolment for its Phase I clinical trial to study safety and tolerability of its biodegradable, slow-release ocular implant for the treatment of glaucoma…

Download

PolyActiva commences its first Phase I clinical trial

31-08-2018

Media Announcements

PolyActiva Pty Ltd, a clinical-stage Australian biotechnology company, has recently recruited first patients into its Phase I clinical study designed to show its glaucoma implant is safe and well tolerated…

Download

Precise Control of Drug Loading and Release of an NSAID-polymer Conjugate for Long Term Osteoarthritis Intra-articular Drug Delvery

24-07-2017

Media Publications
Authors:

J. Mater.Chem B (2017), 5, 6221-6226. DOI: 10.1039/C7TB01518F, Published: 24 July 2017. 

Download

The Hydrolysis of Diclofenac Esters: Synthetic Prodrug Building blocks for Biodegradable Drug-Polymer Conjugates

08-09-2015

Media Publications
Authors:

J Pharm Sci (2016) 105, 773-785 (Research Article – Pharmaceutical, Drug Delivery and Pharmaceutrical Technology). DOI:10.1002/jps.24665, Published:8 September 2015.

Download

PolyActiva raises AUD$9.2M in Series B venture funding

19-02-2013

Media Announcements

PolyActiva announced today that it has raised AUD $9.2 Million in a Series B financing round from a consortium of investors including the Medical Research Commercialisation Fund (MRCF) and Brandon Biosciences Fund 1 (BBF1) (both managed by Brandon Capital), Yuuwa Capital and additional participation from angel investors.

Download